Adcock Richard 4

What Happened
Richard Adcock, CEO, President and Director of ImmunityBio (IBRX), had 274,122 restricted stock units (RSUs vest) convert into common shares on February 10, 2026. To satisfy tax withholding, 140,048 of those shares were withheld at $6.93 per share (≈ $970,533). Net shares issued to Adcock from this vesting were 134,074 (274,122 vested − 140,048 withheld). The transactions were reported on a Form 4 filed February 12, 2026.

Key Details

• Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (appears timely).
• Vesting/conversion: 274,122 shares (derivative conversion / RSU vest) — reported as code M.
• Tax withholding: 140,048 shares withheld/disposed at $6.93/share for tax/payment (code F), totaling ≈ $970,533.
• Net shares issued to insider: 134,074 shares.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: RSUs represent contingent rights to one share each; the closing price on Feb 9, 2026 was used to calculate shares withheld. Vesting schedule: 33.33% yearly over three years beginning Feb 10, 2025.

Context
This was a routine equity compensation event (RSU vesting) rather than an open-market purchase or voluntary sale. The withholding of shares to cover taxes is common and does not necessarily indicate a change in insider sentiment. The filing appears timely (filed within two business days of the Feb 10 transaction).